MedPath
FDA Approval

Amikacin Sulfate

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
May 31, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Amikacin(250 mg in 1 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Fresenius Kabi Austria GmbH

Fresenius Kabi USA, LLC

303448575

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Amikacin Sulfate

Product Details

NDC Product Code
63323-815
Application Number
ANDA205604
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS, INTRAMUSCULAR
Effective Date
May 31, 2023
SODIUM METABISULFITEInactive
Code: 4VON5FNS3CClass: IACT
AmikacinActive
Code: N6M33094FDClass: ACTIMQuantity: 250 mg in 1 mL
TRISODIUM CITRATE DIHYDRATEInactive
Code: B22547B95KClass: IACT
SULFURIC ACIDInactive
Code: O40UQP6WCFClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
© Copyright 2025. All Rights Reserved by MedPath